FDA: ANDA during COVID-19 pandemic [BE/BA News]

posted by Helmut Homepage – Vienna, Austria, 2021-01-19 17:27 (492 d 20:50 ago) – Posting: # 22183
Views: 753

Dear all,

last Friday the FDA’s CDER/OGD published a new guidance

Protecting Participants in
Bioequivalence Studies for
Abbreviated New Drug
Applications During the COVID-19
Public Health Emergency


Dif-tor heh smusma 🖖 [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,108 posts in 4,630 threads, 1,567 registered users;
online 11 (1 registered, 10 guests [including 3 identified bots]).
Forum time: Friday 15:18 CEST (Europe/Vienna)

We absolutely must leave room for doubt
or there is no progress and no learning.
There is no learning without having to pose a question.
And a question requires doubt.
People search for certainty.
But there is no certainty.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5